Hutchison China MediTech Limited Stock price London S.E.
Equities
KYG4672N1198
Pharmaceuticals
Sales 2024 * | 686M 0 | Sales 2025 * | 842M 0 | Capitalization | 2.89B 0 |
---|---|---|---|---|---|
Net income 2024 * | -103M - | Net income 2025 * | -6M - | EV / Sales 2024 * | 3.89 x |
Net cash position 2024 * | 217M 0 | Net cash position 2025 * | 184M 0 | EV / Sales 2025 * | 3.21 x |
P/E ratio 2024 * |
-25.2
x | P/E ratio 2025 * |
644
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on Hutchison China MediTech Limited
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 04-12-31 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 08-06-30 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 99-12-31 |
Graeme Jack
BRD | Director/Board Member | 73 | 17-02-28 |
Dan Eldar
BRD | Director/Board Member | 70 | 16-07-31 |
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |